90924-46-2

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 2-oxindole-4-carboxylate is used as a key intermediate in the development of pharmaceuticals for its ability to contribute to the formation of complex molecular structures that can exhibit therapeutic effects.
Used in Agrochemical Production:
In the agrochemical industry, Methyl 2-oxindole-4-carboxylate is utilized as a precursor in the synthesis of various agrochemicals, contributing to the creation of compounds that can enhance crop protection and yield.
Used in Dye Manufacturing:
Methyl 2-oxindole-4-carboxylate is employed as a building block in the production of dyes, where its chemical properties allow for the creation of a wide range of colorants used in various industries.
Used in Organic Synthesis:
As a versatile intermediate, Methyl 2-oxindole-4-carboxylate is used in organic synthesis for its reactivity and potential to form a variety of organic compounds, expanding the scope of chemical research and development.

InChI:InChI=1/C10H9NO3/c1-14-10(13)6-3-2-4-8-7(6)5-9(12)11-8/h2-4H,5H2,1H3,(H,11,12)

Upstream product

• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 93534-73-7 3-Nitro-homophthalsaeure-dimethylester 
• 90771-65-6 methyl 2-(cyanomethyl)-3-nitrobenzoate 
• 98475-07-1 2-bromomethyl-3-nitro-benzoic acid methyl ester 
• 39830-66-5 methyl 1H-indole-4-carboxylate 

Relevant academic research and scientific papers

Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation

A series of AG014699 derivatives containing a novel scaffold of 2,3-dihydro-1H-[1,2]diazepino[4,5,6-cd]indole-1,4(6H)-dione were synthesized and evaluated for their inhibitory activities toward PARP-1 enzyme and two cell lines, MCF-7 cells and the BRCA1-deficient MDA-MB-436 cells. Our results demonstrated that of all AG014699 derivatives synthesized in this work, compounds 6 and 7 showed strong PARP-1 inhibitory activity (IC50 = 3.5 nM and 2.4 nM, respectively), only four and three times less potent than AG014699. Compound 6 also had significantly cell inhibitory activity against both MCF-7 cells (CC50 = 25.8 μM) and the BRCA1-deficient MDA-MB-436 cells (CC50 = 5.4 μM), nearly as good as AG014699, indicating that it can be a promising compound for further evaluation.

Discovery of potent, selective chymase inhibitors via fragment linking strategies

Chymase plays an important and diverse role in the homeostasis of a number of cardiovascular processes. Herein, we describe the identification of potent, selective chymase inhibitors, developed using fragment-based, structure-guided linking and optimizati